We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biosimilar Act Trumps State Laws, Fed. Circ. Rules

Law360, New York (December 14, 2017, 11:01 AM EST) -- The federal biosimilars act prevents drugmakers from using state laws to punish rivals for withholding information about copycat products, the Federal Circuit ruled Thursday.

The unanimous ruling sided with Sandoz Inc. over Amgen Inc. in a long-running and high-stakes battle that has laid out ground rules for the fledgling biosimilars industry. At issue was whether Amgen could use state laws — such as California’s unfair competition law — to compel disclosure of approval applications and manufacturing information that need not be divulged under the Biologics Price...
To view the full article, register now.




Case Information

Case Title

Amgen Inc. et al v. Sandoz Inc. et al

Case Number



California Northern

Nature of Suit



Richard Seeborg

Date Filed

October 24, 2014

Case Title

Amgen Inc. v. Sandoz Inc.

Case Number



Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

March 27, 2015

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.